Levetiracetam Intrapharm Laboratories (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilizing synaptic transmission, it reduces excessive neuronal excitability and limits the spread of epileptic activity, thereby decreasing seizure occurrence.

The dosing regimen for Levetiracetam Intrapharm is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals set the appropriate dose and infusion rate according to current clinical guidelines.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It generally has fewer drug‑enzyme interactions, a favorable tolerability profile, and can be administered intravenously, making it useful when oral therapy is not feasible.

Levetiracetam Intrapharm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

The product is given as an intravenous infusion. Healthcare professionals dilute the solution according to the manufacturer’s instructions and administer it over the prescribed period, typically via a peripheral or central line, while monitoring the patient for any adverse reactions.

Serious risks include severe allergic reactions (e.g., rash, angioedema, anaphylaxis), mood disturbances such as depression or suicidal thoughts, and rare blood dyscrasias like thrombocytopenia. Patients should be monitored closely for any signs of these events, and treatment should be discontinued if they occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications that could markedly reduce its effectiveness.